# US 2022/0275337 A1 · Cellular compositions comprising viral vectors and methods of treatment

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0275337 A1
- Document ID: US20220275337A1
- Status: Published application
- Kind: A1
- Application number: 17/633,063
- Filed: 2020-08-05
- Published: 2022-09-01
- Earliest claimed: 2019-08-05
- Assignees: Mesoblast International Sarl
- Applicants: Mesoblast International Sárl
- Inventors: Dan DEVINE; Nick LOIZOS; Silviu ITESCU
- Web page: https://patentgrep.com/patent/US20220275337A1

## CPC

- C12N 5/0662: {Stem cells}
- A61K 35/28: Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
- A61P 35/00: Antineoplastic agents
- C12N 15/86: Viral vectors
- C12N 2510/00: Genetically modified cells
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present disclosure relates to cellular compositions that are modified to introduce a recombinant virus. Such compositions may be used to treat cancer by delivering vims to cancer cells.

## Claims

### Claim 1

A population of mesenchymal lineage precursor or stem cells, wherein said cells are modified to increase expression of Phosphatase and Tensin Homolog deleted on chromosome 10 alpha (PTENα).

### Claim 2 (depends on 1)

The population of claim 1, wherein the increase in expression of PTENα is sufficient to decrease the level of phos phorylated AKT in modified cells.

### Claim 3 (depends on 1, 2)

The population of claim 1 or claim 2, wherein the increase in expression of PTENα is sufficient to enhance killing of tumour cells.

### Claim 4 (depends on 1, 2, 3)

The population according to any one of claims 1 to 3, wherein the increase in expression of PTENα is sufficient to enhance migration to tumour cells.

### Claim 5 (depends on 1, 2, 3, 4)

5.The population according to any one of claims 1 to 4, wherein the mesenchymal lineage precursor or stem cells are modified to introduce a recombinant virus which comprises a polynucleotide encoding PTENα.

### Claim 6 (depends on 5, 6)

The population of claim 5, wherein the recombinant virus is an oncolytic virus. The population of claim 5 or claim 6, wherein the virus comprises a herpes simplex virus (HSV) backbone.

### Claim 8 (depends on 4, 5, 6, 7)

The population according to any one of claims 4 to 7, wherein between 20% and 80% of cells comprise the recombinant virus.

### Claim 9 (depends on 4, 5, 6, 7, 8)

The population according to any one of claims 4 to 8, wherein the polynucleotide encoding PTENα is operatively linked to a tumour specific promoter or an inducible promoter.

### Claim 10 (depends on 9)

The population of claim 9, wherein the tumour specific promoter is a survivin promoter, COX-2 promoter, PSA promoter, CXCR4 promoter, STAT3 promoter, hTERT promoter, AFP promoter, CCKAR promoter, CEA promoter, erbB2 promoter, E2F1 promoter, HE4 promoter, LP promoter, MUC-1 promoter, TRP1 promoter, Tyr promoter.

### Claim 11 (depends on 4, 5, 6, 7, 8, 9, 10)

The population according to any one of claims 4 to 10, wherein the recombinant virus comprises a capsid protein that binds a tumour-specific cell surface molecule.

### Claim 12 (depends on 11)

The population of claim 11, wherein the capsid protein is a fibre, a penton or hexon protein.

### Claim 13 (depends on 4, 5, 6, 7, 8, 9, 10, 11, 12)

The population according to any one of claims 4 to 12, wherein the recombinant virus comprises a nucleic acid sequence as shown in SEQ ID NO: 1.

### Claim 14 (depends on 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

The population according to any one of claims 4 to 13, wherein the recombinant virus is a HSV.

### Claim 15 (depends on 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)

The population according to any one of claims 3 to 14, wherein the tumour cells are breast cancer or brain cancer cells.

### Claim 16 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)

The population according to any one of claims 1 to 15, wherein the mesenchymal lineage precursor or stem cells are MSCs.

### Claim 17 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

The population according to any one of claims 1 to 16, wherein the mesenchymal lineage precursor or stem cells have been purified by immunoselection.

### Claim 18 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)

The population according to any one of claims 1 to 15, wherein the mesenchymal lineage precursor or stem cell expresses STRO-1.

### Claim 19 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)

The population according to any one of claims 1 to 18, wherein the mesenchymal lineage precursor or stem cells are derived from pluripotent cells.

### Claim 20 (depends on 19)

The population of claim 19, wherein the pluripotent cells are induced pluripotent stem (iPS) cells.

### Claim 21 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20)

The population according to any one of claims 1 to 20, wherein the population of cells has been culture expanded.

### Claim 22 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21)

A method of increasing PTENα expression in a cell, the method comprising contacting the cell with a population according to any one of claims 1-21.

### Claim 23 (depends on 22)

The method of claim 22, wherein the contacted cell is a cancer cell.

### Claim 24 (depends on 22, 23)

The method of claim 22 or claim 23, wherein increasing PTENα expression in the cell reduces the level of phosphorylated AKT in the cell.

### Claim 25 (depends on 22, 23, 24)

The method according to any one of claims 22 to 24, wherein the method is performed in-vivo.

### Claim 26 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21)

A pharmaceutical composition comprising a population according to any one of claims 1 to 21.

### Claim 27 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 26)

A method of treating cancer in a subject, the method comprising administering a population according to any one of claims 1 to 21 or the composition of claim 26.

### Claim 28 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 26)

A method of killing cancer cells, the method comprising contacting a population of cancer cells with a population according to any one of claims 1 to 21 or the composition of claim 26.

### Claim 29 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 26)

A method of delivering mesenchymal lineage precursor or stem cells to cancer cells in a subject, the method comprising administering a population according to any one of claims 1 to 21 or the composition of claim 26.

### Claim 30 (depends on 27, 28, 29)

The method according to any one of claims 27 to 29, wherein the cancer is selected from the group consisting of lung cancer, pancreatic cancer, colorectal cancer, liver cancer, cervical cancer, prostate cancer, breast cancer, endometrial cancer, thyroid cancer, kidney cancer, brain cancer, glioblastoma, osteosarcoma and melanoma.

### Claim 31 (depends on 30)

The method or claim 30, wherein the cancer is breast cancer or brain cancer.

### Claim 32 (depends on 27, 29, 30)

The method according to any one of claim 27, 29 or 30, wherein the population or composition is administered to the subject by intravenous, intra-arterial, intra-tumoral or intraperitoneal administration.

### Claim 33 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21)

Use of a population according to any one of claims 1 to 21 in the manufacture of a medicament for treating cancer.

### Claim 34 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21)

Use of a population according to any one of claims 1 to 21 in the manufacture of a medicament for delivering mesenchymal lineage precursor or stem cells to cancer cells.
